Anti-Coagulants - Zimbabwe

Zimbabwe

The Anti-Coagulants market in Zimbabwe is expected to witness a significant increase in revenue, with projections indicating that it will reach US$1.65m in the year 2024.
Furthermore, it is anticipated that the market will experience a steady annual growth rate of 5.83% from 2024 to 2029, resulting in a market volume of US$2.19m by the end of 2029.
When comparing the revenue generated in the Anti-Coagulants market globally, it is noteworthy that United States is expected to generate the highest revenue, with an estimated amount of US$16,740.00m in 2024.
Zimbabwe's anti-coagulants market is witnessing a surge in demand due to the rising prevalence of cardiovascular diseases in the country.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Zimbabwe has been steadily growing in recent years.

Customer preferences: As the population ages, the demand for anti-coagulants has increased. Additionally, there is a growing awareness of the importance of preventing blood clots and stroke, which has led to more people seeking out anti-coagulant medications.

Trends in the market: One trend in the Zimbabwean anti-coagulants market is a shift towards newer, more expensive medications. Patients are willing to pay a premium for drugs that are more effective and have fewer side effects. Another trend is the increasing availability of generic anti-coagulants, which has led to increased price competition among manufacturers.

Local special circumstances: Zimbabwe has a high prevalence of HIV/AIDS, which can increase the risk of blood clots. This has contributed to the growing demand for anti-coagulants in the country. Additionally, there is a shortage of healthcare professionals in Zimbabwe, which can make it difficult for patients to access the care they need.

Underlying macroeconomic factors: Zimbabwe has experienced significant economic challenges in recent years, including high inflation and a shortage of foreign currency. This has made it difficult for pharmaceutical companies to import the raw materials needed to manufacture anti-coagulants. Additionally, the country's healthcare system has been underfunded for many years, which has limited access to healthcare services for many Zimbabweans.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.